Why do reported median survival figures for Saltikva differ (24, 20.3, 18.6, 13.8 months)?

Question

Accepted Answer

The figures come from different data cuts and patient groups (J Cell Immunol 2026, Table 2 ↗):

Median OS	Patients	What it covers
24 months	interim cut	Interim result (AACR 2023)
20.3 months	20	Mature result: FOLFIRINOX patients who received more than five doses, including expanded-access patients (HR 0.59 vs the 40 same-site historical FOLFIRINOX controls; p=0.063 at the published data cutoff of March 1, 2025, p<0.05 at the latest data recording (October 2026))
18.6 months	25	All analyzed patients, including expanded access program patients and patients who did not meet the trial's minimum dosage criteria
13.8 months	21	Trial patients without the expanded-access group, but including patients who did not meet the trial's minimum dosage criteria

Comparators: 11.56 months OS for the 40 same-site historical FOLFIRINOX controls; 11.7 months OS for FOLFIRINOX in a published meta-analysis.

In the 20 patients who received more than five doses, 70% had a partial response (95% CI 45.5–87.9%), vs a 31.6% objective response rate for FOLFIRINOX alone in the randomized PRODIGE 4/ACCORD 11 trial (Conroy et al., N Engl J Med 2011;364:1817–25 ↗), and in a post-hoc review 16 of those 20 patients (80%) progressed without new metastases (J Cell Immunol 2026;8(2):48–52 ↗).

Note on control groups

The published J Cell Immunol 2026 papers state the control group sizes incorrectly (n=37 FOLFIRINOX, n=31 gemcitabine/nab-paclitaxel) and will be amended.

Sources (6)

Last reviewed 2026-11-05